Julia Wallenborn1,2, Stefan Störk1,2, Sebastian Herrmann1,2, Olga Kukuy1,2, Georg Fette3, Frank Puppe3, Armin Gorski4, Kai Hu1,2, Wolfram Voelker1,2, Georg Ertl1,2, Frank Weidemann5,6,7. 1. Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. 2. Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany. 3. Department of Informatics VI, University of Würzburg, Würzburg, Germany. 4. Department of Cardiothoracic Surgery, Univerity Hospital Würzburg, Würzburg, Germany. 5. Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany. f.weidemann@katharinen-hospital.de. 6. Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany. f.weidemann@katharinen-hospital.de. 7. Innere Medizin II, Katharinen-Hospital Unna, Obere Husemannstrasse 2, 59423, Unna, Germany. f.weidemann@katharinen-hospital.de.
Abstract
OBJECTIVES: We assessed the prevalence of moderately severe or severe mitral regurgitation (MR) justifying edge-to-edge mitral valve (MV) repair (MitraClip(®)) in patients attending the University Hospital Wuerzburg, a tertiary care centre located in Wuerzburg, Germany. BACKGROUND: Transcatheter edge-to-edge MV repair of advanced MR is a non-surgical treatment option in inoperable and high-risk patients. It is unknown how many patients are potentially eligible for MitraClip(®) since several anatomical prerequisites of the MV apparatus have to be met for optimal treatment results. METHODS: Using a novel clinical data warehouse we searched for all patients attached to our Department of Internal Medicine from 01/2008 to 01/2012 with moderately severe or severe MR and aged ≥18 years. The current status of their treatment regime and eligibility for MitraClip(®) was assessed and re-evaluated according to current guidelines and echocardiographic criteria. RESULTS: The search of electronic medical records amongst 43,690 patients employed an innovative validated text extraction method and identified 331 patients with moderately severe or severe MR who had undergone echocardiographic assessment at our institution. Of these, 125 (38 %) received MV surgery and 206 (62 %) medical therapy only. Most patients not undergoing surgery had secondary MR (70 %). After evaluation of medical and echocardiographic data of medically treated patients (n = 206), 81 (39 %) were potential candidates for MitraClip(®) therapy, and 90 (44 %) died during the median follow-up time of 23 months. CONCLUSION: A large fraction of patients with moderately severe or severe MR but not operated was detected. Medically treated patients had a bad prognosis and about 40 % of them were potential candidates for MitraClip(®) therapy.
OBJECTIVES: We assessed the prevalence of moderately severe or severe mitral regurgitation (MR) justifying edge-to-edge mitral valve (MV) repair (MitraClip(®)) in patients attending the University Hospital Wuerzburg, a tertiary care centre located in Wuerzburg, Germany. BACKGROUND: Transcatheter edge-to-edge MV repair of advanced MR is a non-surgical treatment option in inoperable and high-risk patients. It is unknown how many patients are potentially eligible for MitraClip(®) since several anatomical prerequisites of the MV apparatus have to be met for optimal treatment results. METHODS: Using a novel clinical data warehouse we searched for all patients attached to our Department of Internal Medicine from 01/2008 to 01/2012 with moderately severe or severe MR and aged ≥18 years. The current status of their treatment regime and eligibility for MitraClip(®) was assessed and re-evaluated according to current guidelines and echocardiographic criteria. RESULTS: The search of electronic medical records amongst 43,690 patients employed an innovative validated text extraction method and identified 331 patients with moderately severe or severe MR who had undergone echocardiographic assessment at our institution. Of these, 125 (38 %) received MV surgery and 206 (62 %) medical therapy only. Most patients not undergoing surgery had secondary MR (70 %). After evaluation of medical and echocardiographic data of medically treated patients (n = 206), 81 (39 %) were potential candidates for MitraClip(®) therapy, and 90 (44 %) died during the median follow-up time of 23 months. CONCLUSION: A large fraction of patients with moderately severe or severe MR but not operated was detected. Medically treated patients had a bad prognosis and about 40 % of them were potential candidates for MitraClip(®) therapy.
Authors: John S Gottdiener; James Bednarz; Richard Devereux; Julius Gardin; Allan Klein; Warren J Manning; Annitta Morehead; Dalane Kitzman; Jae Oh; Miguel Quinones; Nelson B Schiller; James H Stein; Neil J Weissman Journal: J Am Soc Echocardiogr Date: 2004-10 Impact factor: 5.251
Authors: Ted Feldman; Hal S Wasserman; Howard C Herrmann; William Gray; Peter C Block; Patrick Whitlow; Fred St Goar; Leonardo Rodriguez; Frank Silvestry; Allan Schwartz; Timothy A Sanborn; Jose A Condado; Elyse Foster Journal: J Am Coll Cardiol Date: 2005-10-19 Impact factor: 24.094
Authors: E A Grossi; J D Goldberg; A LaPietra; X Ye; P Zakow; M Sussman; J Delianides; A T Culliford; R A Esposito; G H Ribakove; A C Galloway; S B Colvin Journal: J Thorac Cardiovasc Surg Date: 2001-12 Impact factor: 5.209
Authors: A M Gillinov; P N Wierup; E H Blackstone; E S Bishay; D M Cosgrove; J White; B W Lytle; P M McCarthy Journal: J Thorac Cardiovasc Surg Date: 2001-12 Impact factor: 5.209
Authors: J P Singh; J C Evans; D Levy; M G Larson; L A Freed; D L Fuller; B Lehman; E J Benjamin Journal: Am J Cardiol Date: 1999-03-15 Impact factor: 2.778
Authors: Vuyisile T Nkomo; Julius M Gardin; Thomas N Skelton; John S Gottdiener; Christopher G Scott; Maurice Enriquez-Sarano Journal: Lancet Date: 2006-09-16 Impact factor: 79.321
Authors: Audrey H Wu; Keith D Aaronson; Steven F Bolling; Francis D Pagani; Kathy Welch; Todd M Koelling Journal: J Am Coll Cardiol Date: 2005-02-01 Impact factor: 24.094
Authors: Mariana Mirabel; Bernard Iung; Gabriel Baron; David Messika-Zeitoun; Delphine Détaint; Jean-Louis Vanoverschelde; Eric G Butchart; Philippe Ravaud; Alec Vahanian Journal: Eur Heart J Date: 2007-03-09 Impact factor: 29.983
Authors: O Alfieri; F Maisano; M De Bonis; P L Stefano; L Torracca; M Oppizzi; G La Canna Journal: J Thorac Cardiovasc Surg Date: 2001-10 Impact factor: 5.209
Authors: Bernard Iung; Gabriel Baron; Eric G Butchart; François Delahaye; Christa Gohlke-Bärwolf; Olaf W Levang; Pilar Tornos; Jean-Louis Vanoverschelde; Frank Vermeer; Eric Boersma; Philippe Ravaud; Alec Vahanian Journal: Eur Heart J Date: 2003-07 Impact factor: 29.983
Authors: Robert Schueler; Can Öztürk; Jan-Malte Sinning; Nikos Werner; Armin Welz; Christoph Hammerstingl; Georg Nickenig Journal: Clin Res Cardiol Date: 2016-12-21 Impact factor: 5.460
Authors: S Ludwig; D Kalbacher; N Schofer; A Schäfer; B Koell; M Seiffert; J Schirmer; U Schäfer; D Westermann; H Reichenspurner; S Blankenberg; E Lubos; L Conradi Journal: Clin Res Cardiol Date: 2020-10-19 Impact factor: 5.460
Authors: Michael M Kreusser; Andreas Weber; Nicolas A Geis; Leonie Grossekettler; Martin J Volz; Sonja Hamed; Hugo A Katus; Sven T Pleger; Norbert Frey; Philip W Raake Journal: ESC Heart Fail Date: 2021-09-08